Jin Ding

7.7k citations

97 papers · 4.8k indexed · h-index 40

Impact in

Cancer Research top 0.5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Cancer, Hypoxia, and Metabolism
Hepatology top 1%
- Liver physiology and pathology
- Hepatocellular Carcinoma Treatment and Prognosis

Papers in ⓘ

Cancer Research 40
- Cancer-related molecular mechanisms research 15
- MicroRNA in disease regulation 13
- NF-κB Signaling Pathways 8
- Cancer, Lipids, and Metabolism 7
Hepatology 18
- Liver physiology and pathology 14
- Hepatocellular Carcinoma Treatment and Prognosis 7

Co-authors: Hongyang Wang (29 shared papers)Beifang Ning (18 shared papers)Wei‐Fen Xie (16 shared papers)Wen Sun (20 shared papers)Daimin Xiang (11 shared papers)Zhuo Cheng (10 shared papers)Tao Han (9 shared papers)Cheng Chen (7 shared papers)
Journals: Hepatology (8 papers)Journal of Hepatology (6 papers)Cancer Letters (5 papers)Cancer Research (5 papers)Journal of Biological Chemistry (4 papers)
Partner nations: China United States Hong Kong

In The Last Decade

Jin Ding

92 papers receiving 4.8k citations

Peers

Countries citing papers authored by Jin Ding

Since Specialization

Citations

This map shows the geographic impact of Jin Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jin Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jin Ding more than expected).

Fields of papers citing papers by Jin Ding

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jin Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jin Ding. The network helps show where Jin Ding may publish in the future.

Co-authors

The 25 scholars most cited alongside Jin Ding, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jin Ding Line = papers co-authored together Jin Ding links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 97 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Ptpn11/Shp2 Acts as a Tumor Suppressor in Hepatocellular Carcinogenesis Cancer Cell ·Emilie A. Bard-Chapeau, Shuangwei Li, Jin Ding, Sharon S. Zhang, Helen He Zhu, Frédéric Princen, Dong Fang, Tao Han, Béatrice Bailly‐Maitre, Valeria Poli, Nissi Varki, Hongyang Wang, Gen‐Sheng Feng	2011	276
2	Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis Journal of Hepatology ·Xue Wang, Wen Sun, Weifeng Shen, Mingyang Xia, Cheng Chen, Daimin Xiang, Beifang Ning, Xiuliang Cui, Hengyu Li, Xiaofeng Li, Jin Ding, Hongyang Wang	2016	255
3	The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma Journal of Hepatology ·Lei Chen, He‐Xin Yan, Wen Yang, Liang Hu, Le-Xin Yu, Qiong Liu, Li Liang, Dandan Huang, Jin Ding, Feng Shen, Weiping Zhou, Mengchao Wu, Hongyang Wang	2008	198
4	Hepatocyte Nuclear Factor 4α Suppresses the Development of Hepatocellular Carcinoma Cancer Research ·Beifang Ning, Jin Ding, Chuan Yin, Wei Zhong, Kun Wu, Xin Zeng, Wen Yang, Yue-Xiang Chen, Junping Zhang, Xin Zhang, Hongyang Wang, Wei‐Fen Xie	2010	194
5	Cancer-associated fibroblasts promote hepatocellular carcinoma metastasis through chemokine-activated hedgehog and TGF-β pathways Cancer Letters ·Jiao Liu, Sheng Chen, Wei Wang, Beifang Ning, Fei Chen, Weifeng Shen, Jin Ding, Wansheng Chen, Wei‐Fen Xie, Xin Zhang	2016	185
6	The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis Gut ·Daimin Xiang, Wen Sun, Beifang Ning, Tengfei Zhou, Xiaofeng Li, Wei Zhong, Zhuo Cheng, Mingyang Xia, Xue Wang, Xing Deng, Wei Wang, Hengyu Li, Xiuliang Cui, Shichao Li, Bin Wu, Wei‐Fen Xie, Hongyang Wang, Jin Ding	2017	181
7	ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α Journal of Hepatology ·Fuquan Wu, Tian Fang, Le‐Xing Yu, Guishuai Lv, Hongwei Lv, Liang Dong, Ting Li, Changzheng Wang, Yexiong Tan, Jin Ding, Yao Chen, Liang Tang, Linna Guo, Shanhua Tang, Wen Yang, Hongyang Wang	2016	179
8	Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development Hepatology ·Kun Wu, Jin Ding, Cheng Chen, Wen Sun, Beifang Ning, Wen Wen, Lei Huang, Tao Han, Wen Yang, Chao Wang, Li Zhong, Mengchao Wu, Gen‐Sheng Feng, Wei‐Fen Xie, Hongyang Wang	2012	170
9	Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation Journal of Hepatology ·Mark Kin Fai, Eunice Y. Lau, Hoi-Wing Leung, Jessica Lo, Nicole P. Ho, Lily K. Cheng, Stephanie Ma, Chi Ho Lin, John A. Copland, Jin Ding, Regina Cheuk‐Lam Lo, Irene Oi‐Lin Ng, Terence K. Lee	2017	139
10	The RNA-binding protein RBM3 promotes cell proliferation in hepatocellular carcinoma by regulating circular RNA SCD-circRNA 2 production EBioMedicine ·Wei Dong, Zhihui Dai, Fuchen Liu, Xinggang Guo, Chun-mei Ge, Jin Ding, Hui Liu, Fu Yang	2019	135
11	Shp2 promotes liver cancer stem cell expansion by augmenting β‐catenin signaling and predicts chemotherapeutic response of patients Hepatology ·Daimin Xiang, Zhuo Cheng, Hui Liu, Xue Wang, Tao Han, Wen Sun, Xiaofeng Li, Wen Yang, Cheng Chen, Mingyang Xia, Na Liu, Shengyong Yin, Guang‐Zhi Jin, Terence K. Lee, Liwei Dong, He-Ping Hu, Hongyang Wang, Jin Ding	2016	127
12	PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients Journal of Hepatology ·Tao Han, Daimin Xiang, Wen Sun, Na Liu, Huanlin Sun, Wen Wen, Weifeng Shen, Ruoyu Wang, Cheng Chen, Xue Wang, Zhuo Cheng, Hengyu Li, Mengchao Wu, Wen‐Ming Cong, Gen‐Sheng Feng, Jin Ding, Hongyang Wang	2015	124
13	Chronic inflammation‐elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance Hepatology ·Xiaofeng Li, Cheng Chen, Daimin Xiang, Le Qu, Wen Sun, Xinyuan Lu, Tengfei Zhou, Shuzhen Chen, Beifang Ning, Zhuo Cheng, Mingyang Xia, Weifeng Shen, Wen Yang, Wen Wen, Terence K. Lee, Wen‐Ming Cong, Hong‐Yang Wang, Jin Ding	2017	104
14	m6A RNA methylation-mediated HNF3γ reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance Signal Transduction and Targeted Therapy ·Tengfei Zhou, Shichao Li, Daimin Xiang, Junyu Liu, Wen Sun, Xiuliang Cui, Beifang Ning, Xiao Li, Zhuo Cheng, Weiqi Jiang, Cheng Zhang, Xijun Liang, Li Liang, Xin Cheng, Hui Liu, Hongyang Wang, Jin Ding	2020	100
15	Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib Journal of Hepatology ·Man Tong, Noélia Che, Lei Zhou, Steve T. Luk, Phillis W. Kau, Stella Chai, Esw Ngan, Chung Mau Lo, Kwan Man, Jin Ding, Terence K. Lee, Stephanie Ma	2018	99
16	Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance Gut ·Daimin Xiang, Wen Sun, Tengfei Zhou, Cheng Zhang, Zhuo Cheng, Shichao Li, Weiqi Jiang, Ruoyu Wang, Gongbo Fu, Xiuliang Cui, Guojun Hou, Guang‐Zhi Jin, Hengyu Li, Cai-Ying Hou, Hui Liu, Hongyang Wang, Jin Ding	2019	97
17	Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma Hepatology ·Jian‐Hong Fang, Li Xu, Li‐Ru Shang, C. Pan, Jin Ding, Yunqiang Tang, Hui Liu, Chu‐Xing Liu, Jia‐Lin Zheng, Yaojun Zhang, Zhongguo Zhou, Jing Xu, Limin Zheng, Minshan Chen, Shi‐Mei Zhuang	2018	92
18	Cyclin G1–mediated epithelial-mesenchymal transition via phosphoinositide 3-kinase/Akt signaling facilitates liver cancer progression Hepatology ·Wen Wen, Jin Ding, Wen Sun, Jing Fu, Yao Chen, Kun Wu, Beifang Ning, Tao Han, Lei Huang, Cheng Chen, Dong Xie, Zhong Li, Gen‐Sheng Feng, Mengchao Wu, Wei‐Fen Xie, Hongyang Wang	2012	91
19	miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy Gut ·Wenping Xu, Jinpei Liu, Jifeng Feng, Changpeng Zhu, Yuan Yang, Weiping Zhou, Jin Ding, Chenkai Huang, Yalu Cui, Chen‐Hong Ding, Xin Zhang, Bin Lü, Wei‐Fen Xie	2019	88
20	Hepatocyte nuclear factor 4α-nuclear factor-κB feedback circuit modulates liver cancer progression Hepatology ·Beifang Ning, Jin Ding, Jiao Liu, Chuan Yin, Wenping Xu, Wen‐Ming Cong, ZhongXiang Zhang, Fei Chen, Tao Han, Xing Deng, Peiqin Wang, Caifeng Jiang, Junping Zhang, Xin Zhang, Hongyang Wang, Wei‐Fen Xie	2014	87

About Jin Ding

Jin Ding is a scholar working on Cancer Research, Hepatology, Molecular Biology, Cell Biology and Oncology, having authored 97 papers that have together received 4.8k indexed citations. Recurring topics across this work include RNA modifications and cancer (15 papers), Cancer-related molecular mechanisms research (15 papers), Liver physiology and pathology (14 papers), MicroRNA in disease regulation (13 papers), NF-κB Signaling Pathways (8 papers), Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Cancer, Lipids, and Metabolism (7 papers) and Circular RNAs in diseases (7 papers). The work is most often cited by research in Cancer Research (2.0k citations), Hepatology (821 citations), Molecular Biology (3.0k citations), Oncology (1.0k citations) and Immunology (645 citations). Jin Ding has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Hongyang Wang, Beifang Ning, Wei‐Fen Xie, Wen Sun, Daimin Xiang, Zhuo Cheng, Tao Han, Cheng Chen, Gen‐Sheng Feng and Kun Wu. Their work appears in journals such as Hepatology, Journal of Hepatology, Cancer Letters, Cancer Research and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact